CAMBRIDGE, Mass.--(BUSINESS WIRE)--Editas Medicine, a transformative genome editing company, today announced the appointment of Katrine S. Bosley as chief executive officer. Ms. Bosley brings to Editas more than 20 years of experience in the biotechnology industry and has been a leader in emerging companies with broad platforms for innovative medicines.
"Katrine's scope of experience spans all stages of research, development and commercialization, a wide variety of diseases, and the gamut of business and financial strategy," said Kevin Bitterman, Ph.D., member of the board of directors and former interim president, Editas Medicine. "I know she will bring all of these capabilities to bear in building Editas and advancing genome editing as a new therapeutic class. We're very excited to have her at the helm."